日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score and Endocrine Responsiveness according to ADAPT

完善辅助性 CDK4/6 抑制剂的风险评估,超越临床试验纳入标准:根据 ADAPT 整合复发评分和内分泌反应性

Braun, Michael; Gluz, Oleg; Kuemmel, Sherko; Nitz, Ulrike; Luedtke-Heckenkamp, Kerstin; Darsow, Maren; Forstbauer, Helmut; Polata, Silke; Grischke, Eva-Maria; Uleer, Christoph; Aktas, Bahriye; Schumacher, Claudia; Zu Eulenburg, Christine; Kates, Ronald; Burmeister, Sandy; Graeser, Monika; Wuerstlein, Rachel; Baehner, Rick; Christgen, Matthias; Kreipe, Hans Heinrich; Harbeck, Nadia

Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial

在WSG-ADAPT-TN试验中,免疫调节基因网络可预测三阴性乳腺癌患者对降阶梯、不含蒽环类药物的新辅助化疗的治疗反应和生存期。

Korbie, Darren; Stirzaker, Clare; Gluz, Oleg; Zu Eulenburg, Christine; Nitz, Ulrike; Christgen, Matthias; Kuemmel, Sherko; Grischke, Eva-Maria; Forstbauer, Helmut; Braun, Michael; Warm, Mathias; Hackmann, John; Uleer, Christoph; Aktas, Bahriye; Schumacher, Claudia; Wuerstlein, Rachel; Pelz, Enrico; Kreipe, Hans Heinrich; Clark, Susan J; Trau, Matt; Graeser, Monika; Harbeck, Nadia

A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders

预测性内分泌抵抗指数能够准确区分管腔型乳腺癌治疗的有效者和无效者。

Zhang, Guokun; Jurinovic, Vindi; Bartels, Stephan; Christgen, Matthias; Christgen, Henriette; Kandt, Leonie Donata; Mishieva, Lidiya; Ni, Hua; Raap, Mieke; Klein, Janin; Katzke, Anna-Lena; Hofmann, Winfried; Steinemann, Doris; Kates, Ronald E; Gluz, Oleg; Graeser, Monika; Kümmel, Sherko; Nitz, Ulrike; Plass, Christoph; Lehmann, Ulrich; Zu Eulenburg, Christine; Mansmann, Ulrich; Gerhäuser, Clarissa; Harbeck, Nadia; Kreipe, Hans H

Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial

三阴性乳腺癌患者的基因改变、治疗反应和生存率:一项随机临床试验的二次分析

Richters, Lisa; Gluz, Oleg; Weber-Lassalle, Nana; Christgen, Matthias; Haverkamp, Heinz; Kuemmel, Sherko; Kayali, Mohamad; Kates, Ronald E; Grischke, Eva-Maria; Altmüller, Janine; Forstbauer, Helmut; Thiele, Holger; Braun, Michael; Warm, Mathias; Ossowski, Anna; Wuerstlein, Rachel; Ernst, Corinna; Graeser, Monika; Linn, Sabine C; Nitz, Ulrike; Hauke, Jan; Kreipe, Hans Heinrich; Schmutzler, Rita K; Hahnen, Eric; Harbeck, Nadia

Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292)

HR阳性HER2阴性早期乳腺癌的内分泌反应评估:WSG ADAPTcycle试验中局部与中心Ki67测量的一致性(n = 5292)

Hamann, M; Christgen, M; Gluz, O; Nitz, U; Kuemmel, S; Braun, M; Thill, M; Wuerstlein, R; Wimberger, P; Hartkopf, A; Schem, C; Zaiss, M; Bjelic-Radisic, V; Just, M; Veselinovic, K; Vincent, M; Graeser, M; Krauss, K; Hoffmann, O; Lüdtke-Heckenkamp, K; Kates, R E; Zu Eulenburg, C; Jóźwiak, K; Burmeister, S; Hauptmann, M; Baehner, F; Schmid, P; Kreipe, H-H; Harbeck, N

Integrative analysis of RNA expression signatures and recurrent genomic alterations before treatment: link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancer

治疗前RNA表达特征和复发性基因组改变的整合分析:与管腔型乳腺癌的绝经状态、短期内分泌治疗反应和无病生存期相关

Zhang, G; Ni, H; Mishieva, L; Bartels, S; Christgen, M; Christgen, H; Kandt, L D; Raap, M; Kates, R E; Gluz, O; Graeser, M; Kümmel, S; Nitz, U; Plass, C; Mansmann, U; Zu Eulenburg, C; Gerhäuser, C; Kreipe, H H; Harbeck, N

Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registry

参与WSG PlanB试验的激素受体阳性早期乳腺癌患者经基因表达分析预筛选后的长期预后数据:WSG PlanB注册研究的10年生存结果

Nitz, U; Graeser, M; Gluz, O; Kümmel, S; Just, M; Jackisch, C; Zu Eulenburg, C; Christgen, M; Harbeck, N

Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers

利用常规免疫组化标志物预测HER2阴性乳腺癌患者新辅助化疗后的病理完全缓解

Häberle, Lothar; Erber, Ramona; Gass, Paul; Hein, Alexander; Niklos, Melitta; Volz, Bernhard; Hack, Carolin C; Schulz-Wendtland, Rüdiger; Huebner, Hanna; Goossens, Chloë; Christgen, Matthias; Dörk, Thilo; Park-Simon, Tjoung-Won; Schneeweiss, Andreas; Untch, Michael; Nekljudova, Valentina; Loibl, Sibylle; Hartmann, Arndt; Beckmann, Matthias W; Fasching, Peter A

HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN

HER2低表达状态作为一种独特的乳腺癌亚型:是谬论还是事实?对WSG试验WSG-ADAPT-HR+/HER2-、WSG-PlanB和WSG-ADAPT-TN的分析

Schmidt, Gilda; Gluz, Oleg; Christgen, Matthias; Reinisch, Mattea; Kümmel, Sherko; Nitz, Ulrike; Braun, Michael; Aktas, Bahriye; Lüdtke-Heckenkamp, Kerstin; Forstbauer, Helmut; Grischke, Eva-Maria; Schumacher, Claudia; Mahlberg, Rolf; Malter, Wolfram; Reimer, Toralf; Nuding, Benno; Stefek, Andrea; Wuerstlein, Rachel; Graeser, Monika; Jóźwiak, Katarzyna; Burmeister, Sandy; Zu Eulenburg, Christine; Lauseker, Michael; Kolberg-Liedtke, Cornelia; Prat, Aleix; Schmid, Peter; Baehner, Rick; Kreipe, Hans Heinrich; Solomayer, Erich-Franz; Harbeck, Nadia

Afadin loss induces breast cancer metastasis through destabilisation of E-cadherin to F-actin linkage.

Afadin 的缺失通过破坏 E-钙黏蛋白与 F-肌动蛋白的连接而诱发乳腺癌转移

Rätze Max Ak, Enserink Lotte Nfl, Ishiyama Noboru, van Kempen Sven, Veltman Christina Hj, Nijman Isaac J, Haakma Wisse E, Caldas Carlos, Bernards René, van Diest Paul J, Christgen Matthias, Koorman Thijs, Derksen Patrick Wb